Prospect for Investors With Considerable Losses to Lead the Ocugen, Inc. Class Action Lawsuit

SAN DIEGO, July 02, 2021–(Business WIRE)–Robbins Geller Rudman & Dowd LLP announces purchasers of Ocugen, Inc. (NASDAQ:OCGN) securities in between February 2, 2021 and June 10, 2021, inclusive (the “Course Interval”) have right until August 17, 2021 to request appointment as direct plaintiff in the Ocugen class motion lawsuit. The situation is captioned Nicanor v. Ocugen, Inc., No. 21-cv-02725, and is assigned to C. Darnell Jones, II of the Jap District of Pennsylvania. The Ocugen class motion lawsuit costs Ocugen and particular of its executives with violations of the Securities Trade Act of 1934.

If you would like to serve as lead plaintiff of the Ocugen class action lawsuit or have issues concerning your rights relating to the Ocugen course motion lawsuit, you should present your information and facts here or get in touch with counsel, J.C. Sanchez of Robbins Geller, at 800/449-4900 or 619/231-1058 or by using e-mail at [email protected]. Lead plaintiff motions for the Ocugen class action lawsuit will have to be filed with the court docket no later on than August 17, 2021.

Case ALLEGATIONS: The Ocugen course motion lawsuit alleges that, in the course of the Class Period of time, defendants designed bogus and misleading statements and unsuccessful to disclose that: (i) the facts that Ocugen submitted to the U.S. Food stuff and Drug Administration (“Food and drug administration”) was inadequate to assist an Crisis Use Authorization (“EUA”) (ii) Ocugen would not file an EUA with the Food and drug administration and (iii) as a end result, Ocugen’s money statements, as properly as defendants’ statements about Ocugen’s business, functions, and prospects were being wrong and misleading and/or lacked a sensible basis.

On June 10, 2021, Ocugen issued a push launch announcing that it would go after a biologics license software (“BLA”) with the Food and drug administration as an alternative of the earlier announced EUA. In undertaking so, Ocugen exposed that “[t]he Fda provided opinions to Ocugen about the Grasp File the Firm experienced formerly submitted and recommended that Ocugen pursue a BLA submission instead of an EUA software for its vaccine prospect and asked for added data and knowledge. Ocugen is in discussions with the Food and drug administration to have an understanding of the added data necessary to help a BLA submission. The Business anticipates that facts from an more medical demo will be required to guidance the submission.” On this information, the rate of Ocugen inventory fell a lot more than 28%, damaging traders.

THE Guide PLAINTIFF Procedure: The Non-public Securities Litigation Reform Act of 1995 permits any investor who purchased Ocugen securities during the Class Interval to request appointment as lead plaintiff in the Ocugen class action lawsuit. A lead plaintiff is typically the movant with the greatest economical interest in the aid sought by the putative class who is also normal and sufficient of the putative class. A direct plaintiff acts on behalf of all other course members in directing the Ocugen class motion lawsuit. The lead plaintiff can pick a law firm of its alternative to litigate the Ocugen class action lawsuit. An investor’s capability to share in any probable upcoming restoration of the Ocugen course action lawsuit is not dependent upon serving as direct plaintiff.

ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 legal professionals in 9 places of work nationwide, Robbins Geller Rudman & Dowd LLP is the greatest U.S. regulation agency representing investors in securities class actions. Robbins Geller lawyers have obtained numerous of the premier shareholder recoveries in history, including the largest securities course action restoration ever – $7.2 billion – in In re Enron Corp. Sec. Litig. The 2020 ISS Securities Course Motion Providers Prime 50 Report ranked Robbins Geller to start with for recovering $1.6 billion for buyers final calendar year, more than double the amount recovered by any other securities plaintiffs’ company. Remember to take a look at for extra info.

Legal professional advertising and marketing.
Past final results do not promise upcoming results.
Services may perhaps be executed by lawyers in any of our places of work.

Perspective supply version on


Robbins Geller Rudman & Dowd LLP
655 W. Broadway, San Diego, CA 92101 • 619-231-1058
J.C. Sanchez, 800-449-4900
[email protected]